PT-141 nasal spray is Rebody's fastest needle-free bremelanotide route. Early intranasal studies show that bremelanotide can produce measurable effects through the nasal route. The strongest modern efficacy and safety evidence belongs to the FDA-approved 1.75 mg injection, not this compounded bottle.
The spray's case is speed, privacy, and needle avoidance. Keep its formulation, dose, and outcomes separate from Vyleesi.
The short answer
PT-141 is another name used for bremelanotide. It acts at melanocortin receptors involved in central sexual-response pathways.
Rebody's nasal product is compounded at 5 mg/mL in a 3 mL bottle. Your clinician sets the dose, timing, and use. Follow your prescription label.
Current product at a glance
| Fact | Rebody PT-141 nasal spray |
|---|---|
| Active | Bremelanotide, also called PT-141 |
| Form | Nasal spray |
| Concentration | 5 mg/mL |
| Bottle | 3 mL |
| Package price | $199 |
Concentration is not the amount in one spray.
What PT-141 targets
Bremelanotide works through melanocortin signaling rather than the blood-flow pathway used by sildenafil or tadalafil. This places it in the desire and arousal conversation.
Desire, genital arousal, lubrication, erection firmness, orgasm, pain, relationship distress, and hormone status are different problems. One product should not be expected to solve all of them.
What is FDA approved
FDA approved Vyleesi as a 1.75 mg injection for acquired, generalized hypoactive sexual desire disorder in premenopausal women when low desire causes marked distress and is not due to another condition, relationship problem, or medication effect.
That approval does not extend to compounded nasal spray, men, every type of low desire, or a different dose. Rebody's spray is not Vyleesi.
What early intranasal studies found
A small crossover study tested intranasal bremelanotide in 18 premenopausal women with female sexual arousal disorder. More participants reported moderate or high desire after bremelanotide than placebo. The study was preliminary, used one specific research dose, and did not test Rebody's bottle.
An early trial in healthy men and men with mild-to-moderate erectile dysfunction measured pharmacokinetics and erectile response after intranasal PT-141. It reported dose-related exposure and common nausea and flushing. It was a small early-development study, not a modern pivotal trial for the current product.
These studies support nasal-route plausibility. They do not create a dose conversion or guarantee a result.
Nasal spray vs approved injection
Nasal spray avoids needles and takes seconds to use. Injection has the deeper evidence base, a defined FDA-approved dose, and a detailed prescribing label for its approved population.
The routes differ in absorption, peak exposure, variability, adverse effects, and timing. Do not use the injection label to calculate sprays. Do not use an early research dose as a home instruction.
Nasal spray vs troche
Spray wins on administration speed. Troche wins when congestion, nosebleeds, irritation, or dislike of nasal products is the main barrier.
Neither compounded route has a head-to-head outcome trial. The troche has less route-specific human evidence. The spray depends on nasal tolerance.
Use the early nasal studies for the right question
The early intranasal studies matter because they tested bremelanotide through the same broad route. One small study in premenopausal women with sexual arousal disorder evaluated intranasal bremelanotide in a controlled setting. Another early study included healthy men and men with mild-to-moderate erectile dysfunction and measured pharmacokinetics and erectile response after intranasal use.
These studies establish more than a theoretical mechanism. Researchers administered intranasal bremelanotide and measured human responses. They do not establish the outcome, dose, or safety profile of the current 5 mg/mL compounded bottle. The finished device still needs its own evidence.
Define success before a trial
Desire, arousal, genital response, erection quality, distress, and sexual satisfaction are related but different outcomes. Choose the one that created the treatment question. A product can change one dimension without fixing the whole experience.
Record nausea, flushing, headache, nasal irritation, and the selected outcome. Include alcohol, relationship stress, and other sexual-health medicines because they can change the night.
If the response is absent, inconsistent, or limited by side effects, bring the record to your clinician.
Blood pressure and nausea matter
The approved injection label warns about transient blood-pressure increases and heart-rate decreases. It is contraindicated in uncontrolled hypertension or known cardiovascular disease. Nausea is common with approved injection use.
Those warnings deserve clinician review for a compounded route too. The nasal spray has its own exposure profile, but a different route does not erase the molecule's safety questions.
Seek urgent help for chest pain, severe headache, fainting, breathing difficulty, facial or tongue swelling, or another severe reaction. Persistent focal skin darkening and severe nausea also need clinical guidance.
What to review before choosing another package
Count completed attempts, not calendar days. For each use, record the selected sexual-response outcome and any side effects. This separates a product that was never used under workable conditions from one that produced a consistent poor response.
Review nasal tolerance as its own result. A bottle can be fast and private yet fail in practice because of congestion, burning, drainage, or nosebleeds. The troche may become the stronger practical option when the nose is the barrier, even though its route-specific evidence is thinner.
Keep blood pressure history and other sexual-health medicines visible. Sildenafil, tadalafil, hormone treatment, antidepressants, alcohol, and relationship conditions can alter the experience or the safety discussion. Do not combine products without your clinician.
Finally, compare the complete $199 package. Confirm 5 mg/mL, the 3 mL fill, shipping, storage, and refill terms. A cheaper bottle with a different pump or concentration is not the same offer.
If the bottle delivered a reliable response but the pump was difficult to use, solve the device question separately from the molecule question. If the pump worked well but nausea or blood-pressure symptoms limited use, changing to another compounded route may not remove the underlying concern. That distinction gives your clinician a clearer next decision.
Questions people ask
Is PT-141 nasal spray FDA approved?
No. Vyleesi is the FDA-approved bremelanotide injection. A compounded nasal spray is a different finished product and route.
Does PT-141 nasal spray work for women?
One small early intranasal study in 18 premenopausal women found subjective signals. It does not establish the outcome of Rebody's bottle.
Does it work for men?
Early intranasal studies measured erectile response in men. Male use remains outside the Vyleesi indication, and the current spray has not been proven as an ED treatment.
How much does it cost?
The current package price is $199. Confirm bottle size, shipping, storage, and refill terms.
Is the nasal spray the same as Vyleesi in a different form?
No. Vyleesi is a specific approved injection with its own dose, label, and pivotal trial data. The RECONNECT phase 3 trials studied that injection, not a nasal bottle. A compounded spray shares the active molecule, but the finished product, route, and exposure are different.
Can a clinician say no?
Yes. A licensed clinician reviews your health history before any prescription. Uncontrolled high blood pressure, known heart disease, or a medicine that changes the safety picture can lead to a different plan or no prescription at all.
What the research does not answer yet
The nasal evidence is old and small. The women's study enrolled 18 participants with sexual arousal disorder, and the men's study was an early development trial. Neither study tested a 5 mg/mL compounded bottle, and neither ran long enough to describe repeated use over many months.
There is no head-to-head trial of nasal spray against the approved injection. There is also no trial of nasal spray against the troche. Any claim that one route works better than another goes beyond the published data.
Safety data has the same limit. The blood-pressure and nausea findings come from the injection label. Nobody has published a matching safety review for repeated use of a compounded nasal bottle, so those warnings stay in force until better data exists.
The studies also leave open how much nasal absorption differs from person to person. Congestion, allergies, and the pump itself can change what reaches the bloodstream. That variability is one reason a clinician, not a chart, sets each patient's prescription.
Who this fits
The spray fits an adult who wants a needle-free bremelanotide option, has a clinician-confirmed reason to try it, and tolerates nasal products well. It also fits someone who values a small, private bottle over a vial and syringe.
It fits less well when the nose is often blocked or irritated, when blood pressure is not under control, or when the main concern is erection firmness alone. Sildenafil and tadalafil act on blood flow, so a clinician may point toward them for that goal instead.
How a Rebody visit works
You complete an online visit with health history questions. A licensed clinician reviews your answers, may ask follow-up questions, and decides whether PT-141 nasal spray suits you. If it does, the prescription and the label carry your directions. Questions about side effects or results go back to that clinician through your account.
Bottom line
PT-141 nasal spray is the practical route for fast, private, needle-free administration. Early nasal studies make the route credible enough to investigate. The approved injection still owns the strongest efficacy and safety evidence.